Filing Flows › Chemours (CC) › Q3 2026 › vs Q2 2026
Chemours (CC) Q3 2026 vs Q2 2026 (quarter over quarter)
Chemours's revenue fell $51.0M (-3%) from $1.6B in Q2 2026 to $1.5B in Q3 2026. The biggest changes: All Segments −$51.0M (-3%); Other Non-Reportable Segment +$0 (0%). Gross margin 15.0% against 18.0% (-3.0 pts).
Chemours, Q3 2026: revenue $1.5B (+3% year over year), operating margin 14.4%, net earnings $196M, operating cash flow $149M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 15.0% | 18.0% | -3.0 pts |
| Operating margin | 14.4% | -0.1% | +14.5 pts |
| Net margin | 12.7% | -17.2% | +29.9 pts |
| Free cash flow margin | 6.4% | 7.2% | -0.8 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| All Segments | $1.5B | $1.6B | −$51.0M | -3% |
| Other Non-Reportable Segment | $13.0M | $13.0M | $0 | 0% |
| Revenue | $1.5B | $1.6B | −$51.0M | -3% |
| Gross profit | $231M | $286M | −$55.0M | -19% |
| Cost of revenue | $1.3B | $1.3B | $4.0M | +0.3% |
| Operating profit | $222M | −$1.0M | $223M | — |
| Operating expenses | $9.0M | $287M | −$278M | -97% |
| Pre-tax earnings | $222M | −$1.0M | $223M | — |
| Net earnings | $196M | −$274M | $470M | — |
| Income tax | $26.0M | $273M | −$247M | -90% |
| Depreciation | $79.0M | $80.0M | −$1.0M | -1% |
| Share-based compensation | $4.0M | $7.0M | −$3.0M | -43% |
| Working capital & other | $130M | −$345M | $475M | — |
| Operating cash flow | $149M | $158M | −$9.0M | -6% |
| Free cash flow (OCF − capex) | $98.0M | $114M | −$16.0M | -14% |
| Capital expenditures | $51.0M | $44.0M | $7.0M | +16% |
Questions
How much did Chemours's revenue grow quarter over quarter in Q3 2026?
Chemours's revenue fell $51.0M (-3%) from $1.6B in Q2 2026 to $1.5B in Q3 2026.
What drove Chemours's revenue change in Q3 2026?
All Segments −$51.0M (-3%); Other Non-Reportable Segment +$0 (0%).